How the Global Fund contributes to the U.S. economy

This map shows the Global Fund’s return on investment to US businesses. Specifically, it details the amount of money made by US companies, by congressional district, as a result of Global Fund investments.

The Global Fund procures extensively from US companies—at least $3.5 billion in the last fifteen years, working directly with manufacturers to bring game-changing American innovations and technologies to market while using its buying power to get the best possible prices. By reducing the burden of the deadliest diseases, the Global Fund helps open access to emerging markets for U.S. firms.

The Global Fund and the U.S. State Department recently partnered with Gilead Sciences and SC Johnson to accelerate access to lifesaving innovations for HIV and malaria. These efforts include expanding access to lenacapavir—Gilead’s long-acting HIV prevention medicine—and to SC Johnson Guardian™, the first spatial repellent to provide up to 12 months of malaria protection. Together, these initiatives aim to protect at least 60 million people from malaria by 2028 and reach at least 2 million people with HIV prevention services.